Zynerba Pharmaceuticals

$3.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today

$0.00 (0.00%) As of 10:07 AM UTC after-hours

Why Robinhood?

You can buy or sell ZYNE and other stocks, options, and ETFs commission-free!

About ZYNE

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA. The listed name for ZYNE is Zynerba Pharmaceuticals, Inc. Common Stock.

CEO

Armando Anido

Employees

Headquarters

Devon, Pennsylvania

Founded

2007

Market Cap

106.57M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.45M

High Today

$3.65

Low Today

$3.51

Open Price

$3.59

Volume

1.44M

52 Week High

$7.45

52 Week Low

$2.55

Collections

Analyst Ratings

71%

of 7 ratings

Buy

71%

Hold

29%

Sell

ZYNE Earnings

-$0.78

-$0.52

-$0.26

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 9, Pre-Market